NBC Securities Inc. Buys 10,211 Shares of Bristol-Myers Squibb (NYSE:BMY)

NBC Securities Inc. raised its stake in shares of Bristol-Myers Squibb (NYSE:BMY - Free Report) by 102,110.0% during the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,221 shares of the biopharmaceutical company's stock after buying an additional 10,211 shares during the period. NBC Securities Inc.'s holdings in Bristol-Myers Squibb were worth $623,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. LaFleur & Godfrey LLC increased its stake in shares of Bristol-Myers Squibb by 3.5% in the fourth quarter. LaFleur & Godfrey LLC now owns 43,551 shares of the biopharmaceutical company's stock worth $2,463,000 after purchasing an additional 1,487 shares during the period. Brighton Jones LLC grew its holdings in Bristol-Myers Squibb by 33.4% in the 4th quarter. Brighton Jones LLC now owns 19,728 shares of the biopharmaceutical company's stock valued at $1,116,000 after buying an additional 4,935 shares during the last quarter. Spire Wealth Management lifted its holdings in shares of Bristol-Myers Squibb by 4.3% during the fourth quarter. Spire Wealth Management now owns 18,338 shares of the biopharmaceutical company's stock worth $1,037,000 after buying an additional 760 shares during the last quarter. GDS Wealth Management bought a new stake in shares of Bristol-Myers Squibb in the fourth quarter valued at approximately $206,000. Finally, Optas LLC bought a new position in Bristol-Myers Squibb during the fourth quarter worth $259,000. Institutional investors and hedge funds own 76.41% of the company's stock.

Insiders Place Their Bets

In other news, EVP Samit Hirawat acquired 4,250 shares of the company's stock in a transaction on Friday, April 25th. The stock was purchased at an average cost of $47.58 per share, with a total value of $202,215.00. Following the acquisition, the executive vice president now owns 83,513 shares of the company's stock, valued at $3,973,548.54. This trade represents a 5.36% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.09% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. UBS Group decreased their price target on shares of Bristol-Myers Squibb from $60.00 to $54.00 and set a "neutral" rating on the stock in a research report on Friday, April 11th. Wells Fargo & Company boosted their price target on Bristol-Myers Squibb from $60.00 to $62.00 and gave the company an "equal weight" rating in a research note on Friday, February 7th. The Goldman Sachs Group reaffirmed a "neutral" rating and issued a $55.00 price target (down previously from $67.00) on shares of Bristol-Myers Squibb in a report on Tuesday, April 8th. William Blair reissued a "market perform" rating on shares of Bristol-Myers Squibb in a report on Friday, April 25th. Finally, Jefferies Financial Group lowered their price objective on Bristol-Myers Squibb from $70.00 to $68.00 and set a "buy" rating on the stock in a research report on Wednesday, April 23rd. Two analysts have rated the stock with a sell rating, thirteen have issued a hold rating, five have issued a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $58.00.

Bristol-Myers Squibb Price Performance

BMY stock traded up $0.58 during midday trading on Friday, reaching $48.42. 9,231,487 shares of the company's stock traded hands, compared to its average volume of 13,048,949. The company has a 50-day simple moving average of $49.56 and a two-hundred day simple moving average of $55.13. The company has a quick ratio of 1.15, a current ratio of 1.25 and a debt-to-equity ratio of 2.90. Bristol-Myers Squibb has a 1-year low of $39.35 and a 1-year high of $63.33. The company has a market cap of $98.54 billion, a price-to-earnings ratio of -10.95, a PEG ratio of 2.07 and a beta of 0.38.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last announced its earnings results on Thursday, April 24th. The biopharmaceutical company reported $1.80 earnings per share for the quarter, beating analysts' consensus estimates of $1.50 by $0.30. The company had revenue of $11.20 billion during the quarter, compared to analyst estimates of $10.77 billion. Bristol-Myers Squibb had a positive return on equity of 13.93% and a negative net margin of 18.53%. The firm's quarterly revenue was down 5.6% compared to the same quarter last year. During the same period last year, the company posted ($4.40) earnings per share. On average, analysts anticipate that Bristol-Myers Squibb will post 6.74 earnings per share for the current year.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.